People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RayzeBio, Inc. | — | Biotechnology | Series D+ | $396.4M | $3.4B | 2021 |
| Nemus Bioscience, Inc. | — | Pharmaceuticals | Series C | $168.4M | $388.7M | 2023 |
Deborah Charych at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Deborah Charych on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Jerel Davis | 1 | 13 |
| Annalisa Jenkins | 1 | 8 |
| Aaron Royston | 1 | 7 |
| Maha Katabi | 1 | 6 |
| Aaron Kantoff | 1 | 6 |
| Praveen Tyle | 1 | 5 |
| PAUL Grayson | 1 | 5 |
| Punit Dhillon | 1 | 4 |
| Gerald W. McLaughlin | 1 | 3 |
| Keith Ward | 1 | 3 |
| Mary Tagliaferri | 1 | 3 |
| Douglas S. Ingram | 1 | 3 |
| John B Hollister | 1 | 2 |
| Angie You | 1 | 2 |
| Alex Rosen | 1 | 2 |
| Arvind Kush | 1 | 2 |
| Ken Song | 1 | 2 |
| Punit S. Dhillon | 1 | 2 |
| James L. Heppell | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.